compounded tirzepatide at $289/month versus $1,000+ for Zepbound
Developed by Eli Lilly and Company, orforglipron represents a fundamental departure from every GLP-1 receptor agonist currently on the market: it is not a peptide, it does not require injection, it does not need an absorption enhancer like SNAC, and it imposes no fasting or water restrictions on patients
But eligibility under IRS rules is the floor, not the ceiling
This shift can affect: posture pelvic alignment walking patterns spinal curvature For some people, these changes are temporary as the body adapts
Tracking food intake can be helpful for patients with obesity, but is contraindicated in patients with an eating disorder
Compounded GLP-1 prescriptions are not FDA-approved and are not the same as brand-name medications